

***Vernex[®] - unique wound healing device with ingredients
from Norwegian salmon roe enters the market in 2019***

Christian Clemm MD MBA, Chief Medical Officer
DNB Nordic Healthcare Conference, December 15th 2016

reGenics 

THE PROBLEM TO BE SOLVED

Wound care – significant market opportunity

- Global wound healing market 145 bn NOK



Basic wound care

Chronic wounds – high unmet medical need

- Accelerating global health problem due to
 - Increasing number of elderly
 - Diabetes epidemic
- Serious condition – leading to hospitalization, amputation and early death



Advanced wound care

THE CHALLENGE WITH TODAY'S SITUATION

Few products with efficacy beyond “cover and protect”


- Accelerating cost of care
- Cost of a few bioactive products too high to be in common use

VERNEX® will be the first biotech product for wound healing based on sources from Norwegian marine industry through innovative research at the University of Oslo.

DATA AND FACTS

Regenics produces bioactive extracts from Norwegian salmon industry

The extracts are capable of stimulating human skin repair



Technology uniquely applied to cytoplasm of salmon roe

Collas et al.

CLONING AND STEM CELLS

Volume 9, Number 1, 2007



Efficacy demonstrated in "wound model"; migration of fibroblasts into a cell-free corridor in vitro

MoA is through cell reprogramming, and the extract is shown to improve reepithelialization of wounds on transplanted human skin.

DATA AND FACTS

Regenics produces bioactive extracts from Norwegian salmon industry

The extracts are capable of stimulating human skin repair




Technology uniquely applied to
cytoplasm of salmon roe
Collas et al.
CLONING AND STEM CELLS
Volume 9, Number 1, 2007

MoA is through cell reprogramming, and the extract is shown to improve reepithelialization of wounds on transplanted human skin.

DATA AND FACTS

Efficacy shown in “proof of principle” trial on burn wounds in human skin*

- Double blinded study design
- Accelerated healing under both normal and hard-to-heal conditions after 5-10 days
- Complete healing only seen under treatment with Vernex[®]



Accelerated complete healing with Vernex[®]

PATENT SITUATION

6 granted and 12 pending patents

- US, EU and ROW. EPO granted March 2016
- Claim coverage: Compositions/extract from fish eggs, formulations, use for cosmetics and wound healing, processing technology
- US patent attorney part of the Management Team


THE MARKET AND KEY COMPETITORS

Wound care market

- *Market of 145 bn NOK in 2016*
- *Strong (>14%) annual growth in advanced wound care*
- *Europe alone 9 million advanced wounds annually, 1/3 of global market*

Competitors

- *In basic wound care there are many players, but low innovation*
- *Bioactive products expensive, unit cost 90 € (Xelma/Mölnlycke), 600 € (Regranex/Systagenic)*




Advanced Wound care


HOW TO REACH THE MARKET

Simple Business Model

Secure funding for CE marked wound healing device....



VERNEX® wound healing device (CE)



through revenue from cosmetics and public funding



LEX® crude extract for cosmetics


Wound care

- **Collaborative research agreement signed with large global wound healing company 2016**
- **Unique cost-effective wound healing device under development. First CE marking and launch expected 2019**

Cosmetics

- **Sales of ingredient direct to cosmetic companies and through distributors creates revenue**
 - *Orkla (AquaDerma)*
 - *Initial sales in Asia*
 - *First continental US “Hi-End” launch expected H1 2017*

THE ORGANIZATION



Very experience team:

15-20 years experience from international pharma, science and sales and marketing:

Branded Consumer Goods
Clinical development
Regulatory, CE marking
Patents, IP (US)



Where we are:

- Collaborative research agreement with a large wound healing company
- Positive proof of principle in wound healing in human skin
- Cash positive from cosmetic sales and public funding (Eurostars, BIA) (2015)
- Submission of C[€] - marking file planned H2 2018


Exit will be through:

- Licensing and/or sale of the company to a
 - branded consumer goods company for cosmetic business, and/or
 - global wound healing company for wound healing device, or
- Listing on appropriate stock exchange

FUTURE CASH FLOW & SCENARIOS



Regenics AS 2016 - 21



* Including public funding, ex efficacy trials

2015:

- **2015: revenue 4,0 mill NOK, result 3,8 mill NOK**

2017:

- **Regenics seeks investment 15 mill , H1 2017 for Clinical efficacy trials program, phase 2-3**

CONTACT INFORMATION

- www.regenics.no
- Email: info@regenics.no

Visit Regenics AS today in meeting room A2 (Arendal) at 15:00 – 16:30

